- Home
- HIE vs NBTX Comparison
HIE vs NBTX Comparison
Compare HIE & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIE
- NBTX
- Stock Information
- Founded
- HIE 2014
- NBTX 2003
- Country
- HIE United States
- NBTX France
- Employees
- HIE N/A
- NBTX N/A
- Industry
- HIE Trusts Except Educational Religious and Charitable
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- HIE Finance
- NBTX Health Care
- Exchange
- HIE Nasdaq
- NBTX Nasdaq
- Market Cap
- HIE 221.9M
- NBTX 201.9M
- IPO Year
- HIE N/A
- NBTX 2020
- Fundamental
- Price
- HIE $12.50
- NBTX $3.89
- Analyst Decision
- HIE
- NBTX Strong Buy
- Analyst Count
- HIE 0
- NBTX 2
- Target Price
- HIE N/A
- NBTX $11.50
- AVG Volume (30 Days)
- HIE 34.9K
- NBTX 7.6K
- Earning Date
- HIE 01-01-0001
- NBTX 11-26-2024
- Dividend Yield
- HIE 5.59%
- NBTX N/A
- EPS Growth
- HIE N/A
- NBTX N/A
- EPS
- HIE N/A
- NBTX N/A
- Revenue
- HIE N/A
- NBTX $45,220,186.00
- Revenue This Year
- HIE N/A
- NBTX N/A
- Revenue Next Year
- HIE N/A
- NBTX N/A
- P/E Ratio
- HIE N/A
- NBTX N/A
- Revenue Growth
- HIE N/A
- NBTX 526.17
- 52 Week Low
- HIE $9.50
- NBTX $3.83
- 52 Week High
- HIE $11.00
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- HIE 62.24
- NBTX 40.72
- Support Level
- HIE $12.45
- NBTX $3.83
- Resistance Level
- HIE $12.38
- NBTX $4.55
- Average True Range (ATR)
- HIE 0.13
- NBTX 0.23
- MACD
- HIE 0.02
- NBTX -0.02
- Stochastic Oscillator
- HIE 92.86
- NBTX 30.86
About HIE Miller/Howard High Income Equity Fund of Beneficial Interest
Miller/Howard High Income Equity Fund is a closed-end, diversified management investment company. The fund's primary investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It invests under normal market conditions, a majority of its total assets in dividend or distribution paying equity securities of U.S. companies and non-U.S. companies traded on U.S. exchanges. Its portfolio of investments consists of securities of different sectors such as Natural Gas Transmission, Real Estate Investment Trusts, Petroleum Refining, Oil and Gas Extraction, Electric Services and others.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.